Lanean...
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by Prchal and Axelrad in the mid-1970s. The knowledge...
Gorde:
| Argitaratua izan da: | J Blood Med |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042185/ https://ncbi.nlm.nih.gov/pubmed/27729820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S102471 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|